Sugi Predict

Sugi Predict / Compounds / SCHEMBL1507474

SCHEMBL1507474

SCHEMBL1507474

C#Cc1cccc(Nc2ncnc3cc(OCCOC(C)=O)c(OCCOC)cc23)c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 17/20 0.84
▸ ERBB2 P04626 7/20 0.84
▸ GAK O14976 3/20 0.84
▸ RIPK2 O43353 2/20 0.84
▸ BUB1 O43683 2/20 0.84
▸ STK10 O94804 2/20 0.84
▸ ABL1 P00519 2/20 0.84
▸ LCK P06239 2/20 0.84
▸ LYN P07948 2/20 0.84
▸ RET P07949 2/20 0.84
▸ SRC P12931 2/20 0.84
▸ FGFR2 P21802 2/20 0.84
▸ FECH P22830 2/20 0.84
▸ KDR P35968 2/20 0.84
▸ FLT3 P36888 2/20 0.84
▸ MAP3K1 Q13233 2/20 0.84
▸ PLK4 O00444 1/20 0.84
▸ CIT O14578 1/20 0.84
▸ AURKA O14965 1/20 0.84
▸ EPHB6 O15197 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30887945 1.00 EGFR (0.84) EGFRERBB2GAKRIPK2BUB1
SCHEMBL1507567 1.00 EGFR (0.84) EGFRERBB2GAKRIPK2BUB1
SCHEMBL1507600 0.96 EGFR (0.78) EGFRERBB2GAKRIPK2BUB1
Erlotinib SCHEMBL20721119 0.94 EGFR (0.89) EGFRERBB2GAKRIPK2BUB1
Erlotinib SCHEMBL482681 0.92 EGFR (0.89) EGFRERBB2GAKRIPK2BUB1
Erlotinib SCHEMBL29120903 0.92 EGFR (0.96) EGFRERBB2GAKRIPK2BUB1
Erlotinib SCHEMBL3667407 0.92 EGFR (1.00) EGFRERBB2GAKRIPK2BUB1
Erlotinib SCHEMBL29351329 0.92 EGFR (1.00) EGFRERBB2GAKRIPK2BUB1
Erlotinib SCHEMBL8413 0.92 EGFR (1.00) EGFRERBB2GAKRIPK2BUB1
Erlotinib SCHEMBL30362833 0.92 EGFR (1.00) EGFRERBB2GAKRIPK2BUB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160303127-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH INC (US) 2016-10-20 — — US claimed
US-20150086545-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH, INC. (US) 2015-03-26 — — US claimed
US-20150056207-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH INC (US) 2015-02-26 — — US claimed
US-20120251530-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS SLIWKOWSKI MARK X (US) 2012-10-04 — — US claimed
US-8163287-B2 Combination therapy of her expressing tumors GENENTECH, INC. (US) 2012-04-24 — — US claimed
EP-2344543-A2 TREATMENT METHOD Genentech, Inc. (US) 2011-07-20 — — EP claimed
JP-2011513427-A — — 2011-04-28 — — JP claimed
EP-2295415-A1 Quinazoline derivatives OSI Pharmaceuticals, Inc. (US) 2011-03-16 — — EP claimed
EP-2257293-A2 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS Genentech, Inc. (US) 2010-12-08 — — EP claimed
WO-2010045345-A2 TREATMENT METHOD GENENTECH, INC. (US) 2010-04-22 — — WO claimed
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS GENENTECH, INC. (US) 2009-09-10 — — US claimed
US-20080175797-A1 PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-07-24 — — US claimed
WO-2007013950-A9 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH INC (US) 2007-03-29 — — WO claimed
WO-2007013950-A2 COMBINATION THERAPY OF HER EXPRESSING TUMORS GENENTECH, INC. (US) 2007-02-01 — — WO claimed
US-20070020261-A1 Combination therapy of her expressing tumors GENENTECH, INC. 2007-01-25 — — US claimed
EP-0817775-B1 QUINAZOLINE DERIVATIVES PFIZER (US) 2001-09-12 — — EP claimed
EP-1110953-A1 Quinazoline derivatives PFIZER INC. (US) 2001-06-27 — — EP claimed
US-5747498-A Alkynyl and azido-substituted 4-anilinoquinazolines PFIZER INC. (US) 1998-05-05 — — US claimed
EP-0817775-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1998-01-14 — — EP claimed
WO-1996030347-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1996-10-03 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150086545-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS ERBB2, EGFR, ERBB3 EGFR 2/4885ERBB2 1/4885GAK 1055/4885
US-20070020261-A1 Combination therapy of her expressing tumors ERBB2, EGFR, ERBB3 EGFR 2/4885ERBB2 1/4885GAK 1055/4885
US-20090226443-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885ERBB2 3/4885GAK 1255/4885
US-20160303127-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885ERBB2 3/4885GAK 1255/4885
US-20150056207-A1 COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS MET, EGFR, ERBB2 EGFR 2/4885ERBB2 3/4885GAK 1255/4885
US-20080175797-A1 PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS EGFR, MUC1, OGFR EGFR 1/4885ERBB2 6/4885GAK 1209/4885
US-20120251530-A1 COMBINATION THERAPY OF HER EXPRESSING TUMORS ERBB2, EGFR, ERBB3 EGFR 2/4885ERBB2 1/4885GAK 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.